Luljeta Abdullahu1*, Vjollca Dedushaj-Fazliu2, Violeta Grajçevci-Uka3, Neshet Rizvanolli4, Idriz Geqari5, Rame Miftari5, Ismet Bajrami5, Fakir Spahiu5, Aferdita Bajqinca5, Armend Jashari5, Ylli Kaçiu5, Aferdita Xhelili5 and Fitore Murati-Abdullahu6
1Department of Nuclear Medicine, University Clinical Center of Kosova, Republic of Kosovo
2Clinic of Endocrinology, University Clinical Center of Kosovo, Republic of Kosovo
3Clinic of Pediatric-Hemato-oncology Department, University Clinical Center of Kosovo, Republic of Kosovo
4MD of Interne Medicine and Master of Nuclear Medicine Et Private Heal Care, Republic of Kosovo
5Department of Nuclear Medicine, University Clinical Center of Kosovo, Republic of Kosovo
6Department of Physiotherapeutic, University Clinical Center of Kosovo, Republic of Kosovo
*Corresponding Author: Luljeta Abdullahu, Department of Nuclear Medicine, University Clinical Center of Kosovo, Republic of Kosovo.
Received: December 08, 2022; Published: December 28, 2022
The aim of this study is to evaluated the outcome of 131I treatment in these to ariants of hyperthyreodism, respectively, to asses the incidence of hypothyroidism in these group of patients compared to group of patients with diffusely enlarged thyroid.
Material and Methods: We observed 226 patients treated with 131I during the five year period, from 2002 to 2007, 174(76.9%) with Graves's disease and diffuse toxic goiter. 25(11%) with multi nodular and 27(11.95%) with toxic nodule.
There were 42(20.80%) males and 184(81.24%) female patients, aged 22 to 70 year.
The treatment dose of 131-I was based on size of the nodule or thyroid gland, respectively, and radioiodine uptake.
Patients are followed for three to five years after they received J-131.
Results: The incidence of hypothyroidism was greater in Graves' disease than in multi nodular toxic and toxic nodular (Toxic Adenoma).
Most of patients ( 96%) with the solitary toxic nodule remained euthyroid up to five years after treated with 131-I.
Keywords. 131-I; Graves' Disease; Multi Nodular Toxic Goiter and Toxic Adenoma
Citation: Luljeta Abdullahu., et al. “Incidence of Hypothyroidism in Patients with Diffuse and Toxic Nodular Goiter Treated with 131J”.Acta Scientific Medical Sciences 7.1 (2023): 83-85b.
Copyright: © 2022 Luljeta Abdullahu., et al.. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.